nodes	percent_of_prediction	percent_of_DWPC	metapath
Suramin—SIRT1—prostate cancer	0.582	1	CbGaD
Suramin—PLA2G4A—Epirubicin—prostate cancer	0.147	1	CbGbCtD
Suramin—F2—urine—prostate cancer	0.00466	0.0479	CbGeAlD
Suramin—P2RY2—epithelium—prostate cancer	0.00455	0.0467	CbGeAlD
Suramin—P2RY2—renal system—prostate cancer	0.00422	0.0434	CbGeAlD
Suramin—SIRT5—prostate gland—prostate cancer	0.00382	0.0393	CbGeAlD
Suramin—P2RX4—prostate gland—prostate cancer	0.00361	0.0372	CbGeAlD
Suramin—SIRT1—prostate gland—prostate cancer	0.00317	0.0326	CbGeAlD
Suramin—ARSA—prostate gland—prostate cancer	0.00313	0.0322	CbGeAlD
Suramin—P2RX4—seminal vesicle—prostate cancer	0.00306	0.0314	CbGeAlD
Suramin—RYR1—prostate gland—prostate cancer	0.00293	0.0301	CbGeAlD
Suramin—SIRT1—seminal vesicle—prostate cancer	0.00268	0.0275	CbGeAlD
Suramin—ARSA—seminal vesicle—prostate cancer	0.00265	0.0272	CbGeAlD
Suramin—SIRT5—renal system—prostate cancer	0.00261	0.0268	CbGeAlD
Suramin—FSHR—testis—prostate cancer	0.00256	0.0263	CbGeAlD
Suramin—SIRT5—urethra—prostate cancer	0.00256	0.0263	CbGeAlD
Suramin—P2RX4—renal system—prostate cancer	0.00246	0.0253	CbGeAlD
Suramin—P2RX4—urethra—prostate cancer	0.00242	0.0249	CbGeAlD
Suramin—SIRT1—epithelium—prostate cancer	0.00233	0.0239	CbGeAlD
Suramin—PLA2G2A—prostate gland—prostate cancer	0.00222	0.0228	CbGeAlD
Suramin—SIRT1—renal system—prostate cancer	0.00216	0.0222	CbGeAlD
Suramin—ARSA—renal system—prostate cancer	0.00213	0.0219	CbGeAlD
Suramin—SIRT1—urethra—prostate cancer	0.00212	0.0218	CbGeAlD
Suramin—PLA2G2A—seminal vesicle—prostate cancer	0.00188	0.0193	CbGeAlD
Suramin—P2RX4—bone marrow—prostate cancer	0.00186	0.0191	CbGeAlD
Suramin—SIRT5—testis—prostate cancer	0.00168	0.0173	CbGeAlD
Suramin—F2—prostate gland—prostate cancer	0.00167	0.0172	CbGeAlD
Suramin—SIRT1—bone marrow—prostate cancer	0.00163	0.0168	CbGeAlD
Suramin—PLA2G2A—epithelium—prostate cancer	0.00163	0.0168	CbGeAlD
Suramin—P2RX4—testis—prostate cancer	0.00159	0.0164	CbGeAlD
Suramin—PLA2G4A—prostate gland—prostate cancer	0.00154	0.0159	CbGeAlD
Suramin—PLA2G2A—renal system—prostate cancer	0.00151	0.0155	CbGeAlD
Suramin—PLA2G2A—urethra—prostate cancer	0.00148	0.0153	CbGeAlD
Suramin—SIRT1—testis—prostate cancer	0.0014	0.0143	CbGeAlD
Suramin—ARSA—testis—prostate cancer	0.00138	0.0142	CbGeAlD
Suramin—PLA2G4A—seminal vesicle—prostate cancer	0.0013	0.0134	CbGeAlD
Suramin—RYR1—testis—prostate cancer	0.00129	0.0133	CbGeAlD
Suramin—F2—epithelium—prostate cancer	0.00123	0.0126	CbGeAlD
Suramin—SIRT5—lymph node—prostate cancer	0.00122	0.0125	CbGeAlD
Suramin—P2RX4—lymph node—prostate cancer	0.00115	0.0119	CbGeAlD
Suramin—F2—renal system—prostate cancer	0.00114	0.0117	CbGeAlD
Suramin—PLA2G4A—renal system—prostate cancer	0.00105	0.0108	CbGeAlD
Suramin—PLA2G4A—urethra—prostate cancer	0.00103	0.0106	CbGeAlD
Suramin—SIRT1—lymph node—prostate cancer	0.00101	0.0104	CbGeAlD
Suramin—ARSA—lymph node—prostate cancer	0.000999	0.0103	CbGeAlD
Suramin—PLA2G2A—testis—prostate cancer	0.000977	0.01	CbGeAlD
Suramin—F2—bone marrow—prostate cancer	0.000863	0.00887	CbGeAlD
Suramin—PLA2G4A—Estradiol—Estradiol valerate/Dienogest—prostate cancer	0.000801	0.262	CbGdCrCtD
Suramin—PLA2G4A—bone marrow—prostate cancer	0.000795	0.00817	CbGeAlD
Suramin—PLA2G2A—lymph node—prostate cancer	0.000708	0.00728	CbGeAlD
Suramin—PLA2G4A—Estradiol—Estramustine—prostate cancer	0.000681	0.223	CbGdCrCtD
Suramin—PLA2G4A—testis—prostate cancer	0.000679	0.00698	CbGeAlD
Suramin—PLA2G4A—Estradiol—Estrone—prostate cancer	0.000541	0.177	CbGdCrCtD
Suramin—PLA2G4A—lymph node—prostate cancer	0.000492	0.00506	CbGeAlD
Suramin—PLA2G4A—Estradiol—Conjugated Estrogens—prostate cancer	0.000476	0.156	CbGdCrCtD
Suramin—PLA2G4A—Estradiol—Ethinyl Estradiol—prostate cancer	0.0004	0.131	CbGdCrCtD
Suramin—PLA2G4A—Betamethasone—Prednisone—prostate cancer	7.82e-05	0.0256	CbGdCrCtD
Suramin—PLA2G4A—Dexamethasone—Prednisone—prostate cancer	7.82e-05	0.0256	CbGdCrCtD
Suramin—F2—Signaling Pathways—ANXA1—prostate cancer	6.96e-06	4.08e-05	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—NOS3—prostate cancer	6.9e-06	4.04e-05	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—MYC—prostate cancer	6.9e-06	4.04e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—NQO1—prostate cancer	6.89e-06	4.03e-05	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—TGFB1—prostate cancer	6.88e-06	4.03e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—PRKCZ—prostate cancer	6.83e-06	4e-05	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—IL2—prostate cancer	6.8e-06	3.98e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—TH—prostate cancer	6.79e-06	3.97e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—PTHLH—prostate cancer	6.77e-06	3.97e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—TGFBR1—prostate cancer	6.77e-06	3.97e-05	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—EGFR—prostate cancer	6.75e-06	3.95e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	6.74e-06	3.95e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—CYP3A4—prostate cancer	6.72e-06	3.93e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	6.68e-06	3.91e-05	CbGpPWpGaD
Suramin—F2—GPCR downstream signaling—PIK3CG—prostate cancer	6.68e-06	3.91e-05	CbGpPWpGaD
Suramin—F2—Hemostasis—EP300—prostate cancer	6.67e-06	3.91e-05	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—MYC—prostate cancer	6.66e-06	3.9e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—AKR1C3—prostate cancer	6.66e-06	3.9e-05	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—TGFB1—prostate cancer	6.65e-06	3.89e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—PRKACB—prostate cancer	6.63e-06	3.88e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—CYP1B1—prostate cancer	6.6e-06	3.87e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—FGFR4—prostate cancer	6.6e-06	3.86e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—PARP1—prostate cancer	6.6e-06	3.86e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—CALCA—prostate cancer	6.52e-06	3.82e-05	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—EGFR—prostate cancer	6.52e-06	3.82e-05	CbGpPWpGaD
Suramin—F2—Hemostasis—SRC—prostate cancer	6.49e-06	3.8e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—PPP3CA—prostate cancer	6.46e-06	3.78e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—THBS1—prostate cancer	6.46e-06	3.78e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—GGT1—prostate cancer	6.39e-06	3.74e-05	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—KRAS—prostate cancer	6.37e-06	3.73e-05	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—PIK3CB—prostate cancer	6.37e-06	3.73e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—CXCL12—prostate cancer	6.37e-06	3.73e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—ANXA1—prostate cancer	6.37e-06	3.73e-05	CbGpPWpGaD
Suramin—F2—Hemostasis—VEGFA—prostate cancer	6.32e-06	3.7e-05	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—PTGS2—prostate cancer	6.31e-06	3.7e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—NCOA1—prostate cancer	6.3e-06	3.69e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—PRKCZ—prostate cancer	6.25e-06	3.66e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—CYP19A1—prostate cancer	6.21e-06	3.63e-05	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—KRAS—prostate cancer	6.16e-06	3.61e-05	CbGpPWpGaD
Suramin—F2—Metabolism of proteins—CXCL8—prostate cancer	6.12e-06	3.58e-05	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—EP300—prostate cancer	6.1e-06	3.57e-05	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—PIK3CG—prostate cancer	6.06e-06	3.55e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—PARP1—prostate cancer	6.04e-06	3.53e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—FGFR4—prostate cancer	6.04e-06	3.53e-05	CbGpPWpGaD
Suramin—ARSA—Metabolism—PIK3CA—prostate cancer	6.03e-06	3.53e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—CASP9—prostate cancer	6e-06	3.51e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—RXRA—prostate cancer	5.99e-06	3.51e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—CALCA—prostate cancer	5.96e-06	3.49e-05	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—SRC—prostate cancer	5.94e-06	3.48e-05	CbGpPWpGaD
Suramin—F2—GPCR downstream signaling—PIK3CD—prostate cancer	5.87e-06	3.44e-05	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—PIK3CA—prostate cancer	5.86e-06	3.43e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	5.83e-06	3.41e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—CXCL12—prostate cancer	5.82e-06	3.41e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—PRKCQ—prostate cancer	5.81e-06	3.4e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—NGFR—prostate cancer	5.81e-06	3.4e-05	CbGpPWpGaD
Suramin—F2—Hemostasis—TGFB1—prostate cancer	5.8e-06	3.4e-05	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—VEGFA—prostate cancer	5.78e-06	3.38e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—COMT—prostate cancer	5.77e-06	3.38e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—GSTP1—prostate cancer	5.74e-06	3.36e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—MAP3K7—prostate cancer	5.74e-06	3.36e-05	CbGpPWpGaD
Suramin—SIRT1—Gene Expression—AKT1—prostate cancer	5.68e-06	3.33e-05	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—TP53—prostate cancer	5.67e-06	3.32e-05	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—PIK3CA—prostate cancer	5.66e-06	3.31e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—ITPR1—prostate cancer	5.65e-06	3.31e-05	CbGpPWpGaD
Suramin—F2—Metabolism of proteins—CTNNB1—prostate cancer	5.65e-06	3.31e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism of lipids and lipoproteins—EP300—prostate cancer	5.56e-06	3.25e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—PIK3CG—prostate cancer	5.55e-06	3.25e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—FGF10—prostate cancer	5.52e-06	3.23e-05	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—PTEN—prostate cancer	5.51e-06	3.22e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—CASP9—prostate cancer	5.48e-06	3.21e-05	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—TP53—prostate cancer	5.47e-06	3.2e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—ADRB2—prostate cancer	5.46e-06	3.2e-05	CbGpPWpGaD
Suramin—F2—GPCR downstream signaling—JAK2—prostate cancer	5.39e-06	3.16e-05	CbGpPWpGaD
Suramin—F2—Hemostasis—KRAS—prostate cancer	5.37e-06	3.15e-05	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—MAP2K1—prostate cancer	5.37e-06	3.14e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—TYMS—prostate cancer	5.34e-06	3.13e-05	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—PIK3CD—prostate cancer	5.33e-06	3.12e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—VAV3—prostate cancer	5.33e-06	3.12e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—PRKCQ—prostate cancer	5.31e-06	3.11e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—NGFR—prostate cancer	5.31e-06	3.11e-05	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—TGFB1—prostate cancer	5.31e-06	3.11e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—GSTM1—prostate cancer	5.28e-06	3.09e-05	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—EP300—prostate cancer	5.25e-06	3.08e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—TGFBR2—prostate cancer	5.25e-06	3.07e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—MAP3K7—prostate cancer	5.25e-06	3.07e-05	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—IL6—prostate cancer	5.19e-06	3.04e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—LPL—prostate cancer	5.18e-06	3.03e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—ITPR1—prostate cancer	5.17e-06	3.03e-05	CbGpPWpGaD
Suramin—F2—GPCR downstream signaling—PIK3CB—prostate cancer	5.12e-06	3e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—FGF10—prostate cancer	5.05e-06	2.96e-05	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—IL6—prostate cancer	5.01e-06	2.93e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—CYP1A1—prostate cancer	5e-06	2.93e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—ADRB2—prostate cancer	5e-06	2.93e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—ERCC2—prostate cancer	4.96e-06	2.91e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—IGF1R—prostate cancer	4.94e-06	2.89e-05	CbGpPWpGaD
Suramin—F2—Hemostasis—PIK3CA—prostate cancer	4.94e-06	2.89e-05	CbGpPWpGaD
Suramin—ARSA—Metabolism—AKT1—prostate cancer	4.93e-06	2.88e-05	CbGpPWpGaD
Suramin—F2—GPCR downstream signaling—CXCL8—prostate cancer	4.92e-06	2.88e-05	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—KRAS—prostate cancer	4.91e-06	2.88e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—MAP2K1—prostate cancer	4.91e-06	2.87e-05	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—JAK2—prostate cancer	4.89e-06	2.87e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—PIK3CD—prostate cancer	4.88e-06	2.86e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—VAV3—prostate cancer	4.87e-06	2.85e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—TGFBR2—prostate cancer	4.8e-06	2.81e-05	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—AKT1—prostate cancer	4.78e-06	2.8e-05	CbGpPWpGaD
Suramin—F2—Hemostasis—TP53—prostate cancer	4.78e-06	2.8e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—LPL—prostate cancer	4.74e-06	2.77e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—ITPR1—prostate cancer	4.73e-06	2.77e-05	CbGpPWpGaD
Suramin—F2—GPCR downstream signaling—IL2—prostate cancer	4.7e-06	2.75e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—PDGFRB—prostate cancer	4.69e-06	2.75e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—MTHFR—prostate cancer	4.66e-06	2.73e-05	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—PIK3CB—prostate cancer	4.65e-06	2.72e-05	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—AKT1—prostate cancer	4.62e-06	2.71e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—PPARA—prostate cancer	4.58e-06	2.68e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—ITGB3—prostate cancer	4.57e-06	2.68e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—IGF1R—prostate cancer	4.52e-06	2.65e-05	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—PIK3CA—prostate cancer	4.51e-06	2.64e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—JAK2—prostate cancer	4.48e-06	2.62e-05	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—CXCL8—prostate cancer	4.47e-06	2.62e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—ERBB3—prostate cancer	4.44e-06	2.6e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—FGFR2—prostate cancer	4.43e-06	2.59e-05	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—TP53—prostate cancer	4.37e-06	2.56e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—LPL—prostate cancer	4.33e-06	2.54e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—CAV1—prostate cancer	4.3e-06	2.52e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—PDGFRB—prostate cancer	4.29e-06	2.51e-05	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—IL2—prostate cancer	4.27e-06	2.5e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—TERT—prostate cancer	4.25e-06	2.49e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—PIK3CB—prostate cancer	4.25e-06	2.49e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—ITGB3—prostate cancer	4.18e-06	2.45e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.11e-06	2.41e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—CXCL8—prostate cancer	4.08e-06	2.39e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—HIF1A—prostate cancer	4.07e-06	2.38e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—ERBB3—prostate cancer	4.06e-06	2.38e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—FGFR2—prostate cancer	4.05e-06	2.37e-05	CbGpPWpGaD
Suramin—F2—Hemostasis—AKT1—prostate cancer	4.03e-06	2.36e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—LEP—prostate cancer	3.97e-06	2.32e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—CAV1—prostate cancer	3.93e-06	2.3e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—PIK3CG—prostate cancer	3.92e-06	2.29e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—IL2—prostate cancer	3.9e-06	2.29e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—TERT—prostate cancer	3.89e-06	2.28e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—KDR—prostate cancer	3.89e-06	2.28e-05	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—PIK3CA—prostate cancer	3.89e-06	2.27e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—ESR1—prostate cancer	3.79e-06	2.22e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—HIF1A—prostate cancer	3.72e-06	2.18e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—INS—prostate cancer	3.71e-06	2.17e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—BAD—prostate cancer	3.7e-06	2.17e-05	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—AKT1—prostate cancer	3.69e-06	2.16e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—CREBBP—prostate cancer	3.63e-06	2.13e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—LEP—prostate cancer	3.63e-06	2.13e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—CAV1—prostate cancer	3.6e-06	2.11e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—PIK3CG—prostate cancer	3.58e-06	2.1e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—APC—prostate cancer	3.58e-06	2.1e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—KDR—prostate cancer	3.56e-06	2.08e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—EGF—prostate cancer	3.54e-06	2.07e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—IRS1—prostate cancer	3.54e-06	2.07e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—ESR1—prostate cancer	3.47e-06	2.03e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—PIK3CD—prostate cancer	3.45e-06	2.02e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—GSK3B—prostate cancer	3.44e-06	2.01e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—INS—prostate cancer	3.39e-06	1.99e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—BAD—prostate cancer	3.38e-06	1.98e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—CREBBP—prostate cancer	3.32e-06	1.95e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—IGF1—prostate cancer	3.28e-06	1.92e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—PIK3CG—prostate cancer	3.28e-06	1.92e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—APC—prostate cancer	3.28e-06	1.92e-05	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—EGFR—prostate cancer	3.26e-06	1.91e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—NOS3—prostate cancer	3.25e-06	1.9e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—IRS1—prostate cancer	3.24e-06	1.9e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—EGF—prostate cancer	3.24e-06	1.9e-05	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—AKT1—prostate cancer	3.17e-06	1.86e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—MAP2K1—prostate cancer	3.17e-06	1.86e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—PIK3CD—prostate cancer	3.15e-06	1.84e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—GSK3B—prostate cancer	3.14e-06	1.84e-05	CbGpPWpGaD
Suramin—F2—GPCR downstream signaling—PIK3CA—prostate cancer	3.12e-06	1.83e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—SERPINE1—prostate cancer	3.12e-06	1.82e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—INS—prostate cancer	3.1e-06	1.82e-05	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—KRAS—prostate cancer	3.08e-06	1.81e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—CREBBP—prostate cancer	3.04e-06	1.78e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—FGF2—prostate cancer	3.02e-06	1.77e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—PIK3CB—prostate cancer	3e-06	1.76e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—IGF1—prostate cancer	3e-06	1.76e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—EGFR—prostate cancer	2.99e-06	1.75e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—PTGS2—prostate cancer	2.98e-06	1.74e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—NOS3—prostate cancer	2.97e-06	1.74e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—MAP2K1—prostate cancer	2.9e-06	1.7e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—JAK2—prostate cancer	2.89e-06	1.69e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—PIK3CD—prostate cancer	2.88e-06	1.69e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—SERPINE1—prostate cancer	2.85e-06	1.67e-05	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—PIK3CA—prostate cancer	2.83e-06	1.66e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—MDM2—prostate cancer	2.82e-06	1.65e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—KRAS—prostate cancer	2.82e-06	1.65e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—ERBB2—prostate cancer	2.78e-06	1.63e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—FGF2—prostate cancer	2.76e-06	1.62e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—PIK3CB—prostate cancer	2.75e-06	1.61e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—NOS3—prostate cancer	2.72e-06	1.59e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—JAK2—prostate cancer	2.64e-06	1.55e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—CXCL8—prostate cancer	2.64e-06	1.54e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—PTEN—prostate cancer	2.59e-06	1.52e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—PIK3CA—prostate cancer	2.59e-06	1.52e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—MDM2—prostate cancer	2.58e-06	1.51e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—CDKN1B—prostate cancer	2.58e-06	1.51e-05	CbGpPWpGaD
Suramin—F2—GPCR downstream signaling—AKT1—prostate cancer	2.55e-06	1.49e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—ERBB2—prostate cancer	2.54e-06	1.49e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—CASP3—prostate cancer	2.53e-06	1.48e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—IL2—prostate cancer	2.52e-06	1.48e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—PIK3CB—prostate cancer	2.51e-06	1.47e-05	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—IL6—prostate cancer	2.51e-06	1.47e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—EP300—prostate cancer	2.47e-06	1.45e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—CCND1—prostate cancer	2.46e-06	1.44e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—CTNNB1—prostate cancer	2.43e-06	1.43e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—CXCL8—prostate cancer	2.41e-06	1.41e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—MMP9—prostate cancer	2.39e-06	1.4e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—CDKN1A—prostate cancer	2.38e-06	1.39e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—PTEN—prostate cancer	2.37e-06	1.39e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—CDKN1B—prostate cancer	2.36e-06	1.38e-05	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—AKT1—prostate cancer	2.31e-06	1.36e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—CASP3—prostate cancer	2.31e-06	1.35e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—IL2—prostate cancer	2.31e-06	1.35e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—IL6—prostate cancer	2.29e-06	1.34e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—EP300—prostate cancer	2.26e-06	1.32e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—CCND1—prostate cancer	2.25e-06	1.32e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—CTNNB1—prostate cancer	2.23e-06	1.3e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—SRC—prostate cancer	2.2e-06	1.29e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—MMP9—prostate cancer	2.18e-06	1.28e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—CDKN1A—prostate cancer	2.17e-06	1.27e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—PTEN—prostate cancer	2.17e-06	1.27e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—VEGFA—prostate cancer	2.14e-06	1.25e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—STAT3—prostate cancer	2.12e-06	1.24e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—AKT1—prostate cancer	2.12e-06	1.24e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—EP300—prostate cancer	2.07e-06	1.21e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—SRC—prostate cancer	2.01e-06	1.18e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—MYC—prostate cancer	1.97e-06	1.15e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—TGFB1—prostate cancer	1.97e-06	1.15e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—VEGFA—prostate cancer	1.96e-06	1.15e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—STAT3—prostate cancer	1.94e-06	1.14e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—EGFR—prostate cancer	1.93e-06	1.13e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—PIK3CA—prostate cancer	1.83e-06	1.07e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—KRAS—prostate cancer	1.82e-06	1.07e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—MYC—prostate cancer	1.8e-06	1.06e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—TGFB1—prostate cancer	1.8e-06	1.05e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—EGFR—prostate cancer	1.76e-06	1.03e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—PIK3CA—prostate cancer	1.67e-06	9.8e-06	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—KRAS—prostate cancer	1.67e-06	9.76e-06	CbGpPWpGaD
Suramin—F2—Signaling Pathways—TP53—prostate cancer	1.62e-06	9.48e-06	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—PIK3CA—prostate cancer	1.53e-06	8.96e-06	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—AKT1—prostate cancer	1.5e-06	8.76e-06	CbGpPWpGaD
Suramin—F2—Signaling Pathways—IL6—prostate cancer	1.48e-06	8.68e-06	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—TP53—prostate cancer	1.48e-06	8.67e-06	CbGpPWpGaD
Suramin—F2—Signaling Pathways—AKT1—prostate cancer	1.37e-06	8.01e-06	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—IL6—prostate cancer	1.36e-06	7.94e-06	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—AKT1—prostate cancer	1.25e-06	7.32e-06	CbGpPWpGaD
